Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | PARP1 | P09874 | 2/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27967764 | 0.88 | KDM4E (0.77) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| Isophthalic Acid SCHEMBL27967640 | 0.88 | KDM4E (0.77) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10372680 | 0.84 | KDM4E (0.72) | KDM4EPARP1GPR84ALDH1A1HPGD | |
| SCHEMBL31609554 | 0.84 | KDM4E (0.72) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5201337 | 0.84 | KDM4E (0.72) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2922430 | 0.84 | KDM4E (0.72) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| Lithium Ion SCHEMBL23216369 | 0.82 | KDM4E (0.70) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| Lithium Ion SCHEMBL29745661 | 0.82 | KDM4E (0.70) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL27592061 | 0.82 | KDM4E (0.69) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9959024 | 0.81 | KDM4E (0.68) | KDM4EPARP1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-114773346-A | Preparation method and application of hippophae rhamnoides extract for inhibiting xanthine oxidase | 东南大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| US-9173395-B2 | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1228069-A2 | BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS | NEUROGEN CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001034603-A2 | BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS | NEUROGEN CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-1992003419-A1 | ISOCARBOSTIRYL COMPOUNDS AND ANTITUMOR USE THEREOF | SYNPHAR LABORATORIES, INC. (CA) | 1992-03-05 | — | — | WO | disclosed |
| US-4393210-A | ANALGESIC, ANTIULCER, ANTIDEPRESSANT, ANTIHISTAMINE, ANTICHOLINERGIC | SEIYAKU CO., LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | KDM4E 1685/4885PARP1 3394/4885CSNK2A2 1595/4885 |
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3900/4885PARP1 2038/4885CSNK2A2 2320/4885 |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | KDM4E 3267/4885PARP1 3264/4885CSNK2A2 836/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3900/4885PARP1 2038/4885CSNK2A2 2320/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | KDM4E 3267/4885PARP1 3264/4885CSNK2A2 836/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | KDM4E 3900/4885PARP1 2038/4885CSNK2A2 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.